Lytle G.,Avedro Inc.
Eye and Contact Lens | Year: 2014
Corneal Cross-linking with Ultraviolet-A Andriboflavin Was Introduced over 15 Years Ago and Has Been Widely Adopted As A Treatm. for Keratoconus. Several Studs. Have Demonstrated the Safety and Efficacy of the Procedure Performed Acc. to A Std. Protocol. Recent Sci. and Technol. Advances Have Highlighted the Opportunity for Optimization of the CXL Procedure Through Modifications to This Protocol. Advances in the Technol. of CXL Include New Riboflavin Formulations, Higher Irradiance UVA Sources, and Programmable UVA Illumination Patterns. Several Lab. and Clin. Studs. Demonstrate That These Modifications May Provide Equivalent Treatm. Effect in Shorter Total Treatm. Times. Additionally, although the Original Purpose of CXL Was to Stabilize the Cornea and Prevent Further Vis. Loss in Keratoconus, Patient-specific Compl. Modeling and Customized CXL with Programmable UVA Treatm. Patterns Demonstrate the Potential for CXL to Be Used As A Means of Improving Corneal Topogr. to Maximize Vis. Rehab. in Patients with Keratoconus. This Rev. Aims to Provide An Overview of These Advances in CXL Technol. Designed to Optimize the Efficiency or Efficacy of the Clin. CXL Procedure. Copyright © 2014 Contact Lens Association of Opthalmologists, Inc.
Avedro Inc. | Date: 2015-04-27
Devices and approaches for monitoring time based photo active agent delivery or photo active marker presence in an eye. A monitoring system is provided for measuring the presence of a photo active marker by illuminating the eye so as to excite the photo-active marker and then observing characteristic emission from the photo active marker. Example systems incorporate Scheimpflug optical systems or slit lamp optical systems to observe cross sectional images of an eye to monitor instantaneous distribution, diffusion pattern, and rate of uptake of a photo active agent applied to an eye. Systems and methods further allow for utilizing the monitored distribution of photo active agent in the eye as feedback for a cross-linking system.
Avedro Inc. | Date: 2014-04-09
A system for applying a treatment to an eye includes a housing having a first end and a second end, a contact element having an open end and a closed end, and a light source disposed within the housing and configured to direct light toward the open end. The contact element is coupled to the first end of the housing at the closed end. The open end is configured to be positioned at an eye.
Avedro Inc. | Date: 2014-10-06
Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O
Avedro Inc. | Date: 2014-03-17
A glaucoma treatment system includes: a cannula body configured to be positioned in an area of Schlemms canal; an illumination guide extending along the cannula body; at least one drug source coupled to the cannula body; a cross-linking agent source coupled to the cannula body; and an illumination source coupled to the illumination guide. The at least one drug source includes a drug that promotes outflow of aqueous humor through the trabecular meshwork and into Schlemms canal. The cannula body delivers the drug from the at least one drug source to the area of Schlemms canal, and in response to changes in the outflow of aqueous humor, delivers the cross-linking agent to the area of Schlemms canal. The illumination guide delivers photo-activating light from the illumination source to the area of Schlemms canal. The photo-activating light activates the cross-linking agent, thereby stabilizing changes in the area of Schlemms canal.